## Milestones:

NC229	2014 (4 mos)	2015 (12 mos)	2016 (12 mos)	2017 (12 mos)	2018 (12 mos)	2019 (8 mos)	Projected major outcome for each objective
Objective 1					1	I	1
1.1 PRRSV immunity and vaccinology							Cross protection amongst PRRSV strains feasible
1.2 PRRSV epidemiology surveillance							Effective biosecurity barriers perfected and completely understood
1.3 Economic Impact of Interventions							Cost effective alternative interventions identified and weighted
Objective 2							
2.1 PEDV							
Diagnostic/lab methods							Serologic and viral procedures optimized and in place
Vaccinology/Epidemiology							Complete understanding of PEDV protective immunity
							Standard PEDV reference reagents in place
							Viral evolution models in place
2.2 Influenza							
Protection of swine herds							Hetrologous protection X swine influenza achieved
Public health implications			<b>→</b>	<b>→</b>	<b>→</b> —		Monitoring on a permanent basis, to protect swine industry and humans alike
2.3 ASFV						1	

Vaccine design and Development				ASFV strain variation understood Feasibility of vaccination accepted and actively investigated
Diagnostic surveillance prevention of infection occurrence		 	 	Optimal standards of ASFV surveillance attained in the US and maintained on a permanent basis